What's happened
A new study analyzing electronic health records from over 600,000 U.S. Veterans with diabetes finds that GLP-1 medications like Ozempic and Mounjaro are associated with lower risks of developing substance use disorders and related harms, including overdose and death. The findings suggest these drugs may target underlying cravings, but do not prove causation.
What's behind the headline?
The study's findings are significant, as they suggest GLP-1 drugs may address the root causes of addiction by modulating brain reward systems. This aligns with earlier smaller studies hinting at the drugs' impact on cravings. However, as an observational analysis, it cannot establish causality, only association. The VA population, predominantly older, white, and male, limits generalizability, though results were consistent across women. If confirmed, these findings could revolutionize addiction treatment, positioning GLP-1 medications as a potential tool for prevention and harm reduction. The mechanism remains unclear, but the drugs' influence on hormones controlling appetite may extend to cravings for substances like alcohol and opioids, offering a promising new avenue for research and therapy.
What the papers say
The Independent reports that the study, published in The BMJ, analyzed electronic health records from over 600,000 VA patients with diabetes, finding that those on GLP-1 medications had lower risks of developing various substance use disorders and related harms. The article quotes Dr. Ziyad Al-Aly, emphasizing the potential of these drugs to target addiction's underlying biology. It also notes limitations, including the VA population's demographics and the observational nature of the study. The Guardian highlights the study's scale and its implications for understanding addiction mechanisms, while AP News summarizes the core findings, emphasizing the potential for GLP-1 drugs to lower hospitalization, overdose, and death risks among existing addicts. All sources agree on the promising but preliminary nature of these findings, calling for further research.
How we got here
Previous research indicated that GLP-1 receptor agonists, used for weight loss and diabetes, could influence brain reward pathways linked to addiction. This large-scale observational study builds on that, analyzing VA health data over three years to explore potential benefits beyond metabolic control, focusing on substance use disorders among patients with diabetes.
Go deeper
More on these topics